Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
The objectives of this study were to formulate and stabilize amorphous formulation of low T(g) drug (Indomethacin, INM) with selected polymers and compare these formulations based on solubility and dissolution rate studies. Eudragit EPO (EPO), Polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), and Polyvinylpyrrolidone K30 (PVPK30) were selected as hydrophilic polymers. The melt extrudates were characterized using differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), intrinsic dissolution rate and solubility studies. The formation of single-phase amorphous form was confirmed by DSC and PXRD. The melt extrudates showed a higher intrinsic dissolution rate (IDR), and solubility compared to the pure drug. The amorphous drug in solid solutions with EPO, PVP-VA, and PVPK30 showed tendency to revert back to crystalline form. However, the rate of reversion was dependent on the nature and concentration of the polymer. The solid solution with high ratio of EPO provided superior stabilization of the amorphous INM from crystallization. The stability of the amorphous form of INM could not be related to the glass transition temperature of the formulation as the mechanism of stabilization with EPO appears to be molecular interaction rather than immobilization. The presence of specific molecular interactions between INM and EPO was also shown by the antiplasticization effect.
Chokshi
Rina J
RJ
Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island, USA. chokshr@wyeth.com
Shah
Navnit H
NH
Sandhu
Harpreet K
HK
Malick
Ahmad W
AW
Zia
Hossein
H
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry*; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D018360:Crystallography, X-Ray; D004339:Drug Compounding; D004355:Drug Stability; D007213:Indomethacin / Q000737:chemistry*; D007700:Kinetics; D011205:Povidone / Q000737:chemistry*; D033362:Powder Diffraction; D011759:Pyrrolidines / Q000737:chemistry*; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013678:Technology, Pharmaceutical / Q000379:methods; D044366:Transition Temperature; D014753:Vinyl Compounds / Q000737:chemistry*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011759:Pyrrolidines; D014753:Vinyl Compounds; C402301:poly(vinylpyrrolidone-co-vinyl-acetate); D011205:Povidone; D007213:Indomethacin